|
|
|
Volumn 26, Issue 5 SUPPL. 16, 1999, Pages 1-6
|
|
A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: Why we should look beyond platinum
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CISPLATIN;
DOCETAXEL;
GEMCITABINE;
IRINOTECAN;
PACLITAXEL;
TAXANE DERIVATIVE;
ARTICLE;
CANCER SURVIVAL;
CLINICAL TRIAL;
HISTORY OF MEDICINE;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
LUNG NON SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
SIDE EFFECT;
SURVIVAL TIME;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CAMPTOTHECIN;
CARCINOMA, NON-SMALL-CELL LUNG;
CISPLATIN;
DEOXYCYTIDINE;
DRUG THERAPY;
HISTORY, 20TH CENTURY;
HUMANS;
LUNG NEOPLASMS;
MEDICAL ONCOLOGY;
PACLITAXEL;
VINBLASTINE;
|
|
EID: 0032694457
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (7)
|
|
References (42)
|
